Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
4.38 (1y: +5%)
Market Cap 232.95 M P/E(ttm)
Enterprise Value 223.05 M P/B 25.72
BTX- AMEX (USA)
BioTime, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$4.38
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt No Debt
BTX's Cash to Debt is ranked higher than
63% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. BTX: No Debt )
BTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt
Equity to Asset -0.366
BTX's Equity to Asset is ranked lower than
94% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. BTX: -0.366 )
BTX' s 10-Year Equity to Asset Range
Min: -17.41   Max: 0.9
Current: -0.37
-17.41
0.9
Interest Coverage No Debt
BTX's Interest Coverage is ranked higher than
67% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 37.90 vs. BTX: No Debt )
BTX' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: 1.79
M-Score: -5.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry		 vs
history
Operating margin (%) -638.60
BTX's Operating margin (%) is ranked lower than
81% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. BTX: -638.60 )
BTX' s 10-Year Operating margin (%) Range
Min: -9788.5   Max: -116.8
Current: -638.6
-9788.5
-116.8
Net-margin (%) -547.3
BTX's Net-margin (%) is ranked lower than
81% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. BTX: -547.3 )
BTX' s 10-Year Net-margin (%) Range
Min: -9471.2   Max: -137.5
Current: -547.3
-9471.2
-137.5
ROE (%) -223.5
BTX's ROE (%) is ranked lower than
94% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. BTX: -223.5 )
BTX' s 10-Year ROE (%) Range
Min: -894.2   Max: -29.3
Current: -223.5
-894.2
-29.3
ROA (%) -72
BTX's ROA (%) is ranked lower than
87% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. BTX: -72 )
BTX' s 10-Year ROA (%) Range
Min: -821.7   Max: -21
Current: -72
-821.7
-21
Revenue Growth (%) 3.4
BTX's Revenue Growth (%) is ranked higher than
69% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BTX: 3.4 )
BTX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 41.4
Current: 3.4
0
41.4
EBITDA Growth (%) 39.2
BTX's EBITDA Growth (%) is ranked higher than
97% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BTX: 39.2 )
BTX' s 10-Year EBITDA Growth (%) Range
Min: -39.6   Max: 44.8
Current: 39.2
-39.6
44.8
EPS Growth (%) 25
BTX's EPS Growth (%) is ranked higher than
94% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BTX: 25 )
BTX' s 10-Year EPS Growth (%) Range
Min: -27.7   Max: 47
Current: 25
-27.7
47
» BTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with BTX



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 25.72
BTX's P/B is ranked lower than
96% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. BTX: 25.72 )
BTX' s 10-Year P/B Range
Min: 5.38   Max: 83
Current: 25.72
5.38
83
P/S 62.57
BTX's P/S is ranked lower than
82% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. BTX: 62.57 )
BTX' s 10-Year P/S Range
Min: 4.83   Max: 500
Current: 62.57
4.83
500
EV-to-EBIT -8.12
BTX's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. BTX: -8.12 )
BTX' s 10-Year EV-to-EBIT Range
Min: 36   Max: 93.1
Current: -8.12
36
93.1

Valuation & Return

vs
industry		 vs
history
Price/Median PS Value 1.7
BTX's Price/Median PS Value is ranked lower than
69% of the 345 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. BTX: 1.7 )
BTX' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 11.8
Current: 1.7
0.1
11.8
Forward Rate of Return (Yacktman) 26.01
BTX's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BTX: 26.01 )
BTX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.5   Max: 21.5
Current: 26.01
4.5
21.5

Business Description

BioTime, Inc. was incorporated in 1990 in the state of California. BioTime is a biotechnology company engaged in two areas of biomedical research and product development. BioTime has historically developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. The Company's primary focus is in the field of regenerative medicine; specifically human embryonic stem cell and induced pluripotent stem cell technology. Its commercial strategy is heavily focused on near-term commercial opportunities including the current line of research products such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem cell lines, and royalties from Hextend. Potential near term therapeutic product opportunities include the launch of HyStem-Rx as a cell delivery device, and the launch of PanC-Dx as a novel blood-based cancer screen. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. The Company plans to develop stem cell products for research and therapeutic use through its subsidiaries. OncoCyte Corporation is developing products and technologies to diagnose and treat cancer. ES Cell International Pte. Ltd., develops and sells hES products for research use. BioTime Asia, Limited sells products for research use and may develop therapies to treat cancer, neurological, and orthopedic diseases. OrthoCyte Corporation is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc., formerly known as Embryome Sciences, Inc. is developing therapies to treat vascular and blood diseases and disorders. Cell Cure Neurosciences Ltd. focuses on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. LifeMap Sciences, Inc. is advancing the development and commercialization of BioTime's embryonic stem cell database and plans to make the database available for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions through paid subscriptions or on a fee per use basis. The Company's blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pressure, and keeps vital organs perfused during surgery and trauma care. Hextend is manufactured and distributed in the U.S. by Hospira, Inc., and in South Korea
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:BT3.Germany
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: ADLR, RENT, BTX, CWST, NVSLD Jul 03 2011 
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial